Revvity (RVTY)

• Market cap: $11.2B
• 1 day: -1.38%
• 5 days: -0.45%
• 1 month: -11.77%
• 3 months: -26.40%
• 6 months: -22.23%
• Year to date: -16.65%
• 1 year: -8.90%
• 5 years: 3.11%
• 10 years: 82.11%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.

Employees: 11,000

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

20% more call options, than puts

Call options by funds: $1.77M | Put options by funds: $1.48M

19% more repeat investments, than reductions

Existing positions increased: 191 | Existing positions reduced: 161

15% more first-time investments, than exits

New positions opened: 69 | Existing positions closed: 60

3.87% more ownership

Funds ownership: 87.62% [Q3] → 91.49% (+3.87%) [Q4]

0% more funds holding

Funds holding: 517 [Q3] → 518 (+1) [Q4]

4% less capital invested

Capital invested by funds: $13.8B [Q3] → $13.2B (-$544M) [Q4]

25% less funds holding in top 10

Funds holding in top 10: 8 [Q3] → 6 (-2) [Q4]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $100 7% upside
• Avg. target: $118 27% upside
• High target: $145 55% upside

7 analyst ratings

• positive: 5 71%
• neutral: 2 29%
• negative: 0 0%

Goldman Sachs Matthew Sykes 43% 1-year accuracy 15 / 35 met price target	34% upside $125	Buy Maintained	29 Apr 2025
JP Morgan Rachel Vatnsdal 69% 1-year accuracy 11 / 16 met price target	7% upside $100	Neutral Maintained	29 Apr 2025
Raymond James Andrew Cooper 22% 1-year accuracy 4 / 18 met price target	29% upside $120	Outperform Reiterated	29 Apr 2025
Baird Catherine Ramsey 37% 1-year accuracy 7 / 19 met price target	34% upside $125	Outperform Maintained	29 Apr 2025
Wells Fargo Brandon Couillard 8% 1-year accuracy 2 / 25 met price target	9% upside $102	Equal-Weight Maintained	17 Apr 2025